about
Socio-economic impact of endovenous thermal ablation techniques.Improving the management of varicose veins.Ambulatory varicosity avulsion later or synchronized (AVULS): a randomized clinical trial.The advent of non-thermal, non-tumescent techniques for treatment of varicose veins.Retrograde inversion stripping as a complication of the ClariVein mechanochemical venous ablation procedureSystematic review of sonographic chronic cerebrospinal venous insufficiency findings in multiple sclerosis.Treatment options, clinical outcome (quality of life) and cost benefit (quality-adjusted life year) in varicose vein treatment.Surgical patch angioplasty of the left main coronary artery.Patterns of short saphenous vein incompetence.The European burden of primary varicose veins.A systematic review and meta-analysis on the role of varicosity treatment in the context of truncal vein ablation.Open repair versus fenestrated endovascular aneurysm repair of juxtarenal aneurysms.Inferior vena cava filters for prevention of venous thromboembolism in obese patients undergoing bariatric surgery: a systematic review.Comparison of microbubble presence in the right heart during mechanochemical and radiofrequency ablation for varicose veins.Pharmacological adjuncts for chronic venous ulcer healing: a systematic review.A Review of the Evidence to Support Neuromuscular Electrical Stimulation in the Prevention and Management of Venous Disease.Internal jugular thrombosis post venoplasty for chronic cerebrospinal venous insufficiency.Neuromuscular electrical stimulation for the prevention of venous thromboembolism.Big Veins, Big Deal - Vein Diameter Affects Disease Severity, not Quality of Life.Cyanoacrylate glue for the treatment of great saphenous vein incompetence in the anticoagulated patient.Factors impacting on patient perception of procedural success and satisfaction following treatment for varicose veins.Carbon monoxide poisoning in a patient with carbon dioxide retention: a therapeutic challenge.The burden of depression in patients with symptomatic varicose veins.Retrograde mechanochemical ablation of the small saphenous vein for the treatment of a venous ulcer.Re. 'An online patient completed aberdeen varicose vein questionnaire can help to guide primary care referrals'.Intra-procedural pain score in a randomised controlled trial comparing mechanochemical ablation to radiofrequency ablation: The Multicentre Venefit™ versus ClariVein® for varicose veins trial.Comparison of disease-specific quality of life tools in patients with chronic venous disease.A multi-centre randomised controlled trial comparing radiofrequency and mechanical occlusion chemically assisted ablation of varicose veins - Final results of the Venefit versus Clarivein for varicose veins trial.Truncal varicose vein diameter and patient-reported outcome measures.Randomised Controlled Trial: Potential Benefit of a Footplate Neuromuscular Electrical Stimulation Device in Patients with Chronic Venous Disease.Acoustic reflectors are visible in the right heart during radiofrequency ablation of varicose veins.Phlebectomies: to delay or not to delay?The Future of Phlebology in Europe.Management of chronic venous disease by primary care.Total preservation of patency and valve function after percutaneous pharmacomechanical thrombolysis using the Trellis®-8 system for an acute, extensive deep venous thrombosis.Mechanochemical ablation versus cyanoacrylate adhesive for the treatment of varicose veins: study protocol for a randomised controlled trialManagement of uncomplicated varicose veins - a case vignette for a clinical decision proposalTo compress or not to compress: The eternal question of the place of compression after endovenous proceduresThe disparate management of superficial venous thrombosis in primary and secondary careImpact of risk scoring on decision-making in symptomatic moderate carotid atherosclerosis
P50
Q35007623-3FB37D9E-D2E5-4175-B593-EAD466FDB958Q35098583-093F4559-D480-4A06-9183-F54D82662221Q35192293-C485FB40-0A91-4E2A-A5BB-0A58EFE32FA0Q35679230-327BE6D7-5B70-4719-AAA6-529B84D96F0AQ35758275-1C91047F-A1D1-4356-A5B2-79D631A1DAD0Q37948747-6CE60B2A-EFB8-4179-AA05-38FE17DCA4C8Q37982021-71092949-07CF-418B-B544-0EB3A56939CBQ38017022-724EBDF0-D99F-469C-B782-C6759B1047ACQ38088596-A20FDD10-BC08-4906-9DF4-806BF0B9065FQ38088612-A73D47BF-D34D-42C9-B4E7-921E2088CF2FQ38241143-0F74EC34-26AA-46FC-9444-B6C082BB11F8Q38252794-4A3DC16C-AD08-4B2D-B2E6-766F57FB17F3Q38323185-321290B9-BE42-4790-9AFF-9839EAE900FEQ38411692-115ED0FD-2EB6-4C69-A493-DD33F5812D89Q38513231-484F798E-E924-448E-A8ED-3C00A53F7FFDQ38952572-98875901-0A64-48B1-A2C2-4E8CD8A77294Q39261705-15493CD8-B56A-4165-A2D2-4A7AFC9376B9Q39370257-469D3BE3-B20B-4373-A96B-0FAB19B3E21AQ39906120-4261CA36-02BD-49D5-AEF5-D7BDC94992D6Q39907775-189CEA8D-522F-41E6-B6BE-9EF87ECC0D77Q40037282-4012EC5E-46AE-41E4-8311-BE9B44C007F8Q42288176-CA369502-6C43-4A1B-AA1D-733B8634C3A0Q43968873-40E70A48-9826-4DCD-B84A-17A797DCEA26Q44015035-71E05B01-D9D8-4720-9332-2E1A4325965CQ44914603-7A6EBCE3-B1A5-4943-AC31-1C2AB458D143Q45743877-B2AC40AD-1857-482B-8578-AA2694EA29E1Q45914596-A6B60D1C-B9EF-409D-9F8B-FC4C3677F0FBQ47427001-2DD9104B-1957-4E3D-8ED2-0830E78CC095Q47554682-70F7E677-0A23-42EA-9860-57DA54AC9A78Q47610345-EE3F9E20-0CE2-4709-AB0A-24E3176315BFQ47831183-82BE2D44-C4E1-4BD7-95C3-119B7528C459Q47999715-FF1FBA76-739B-450D-B22B-E020E01123FEQ48920619-C659DD56-95C7-4378-A9B0-304AE720AB44Q50910488-F339CEE4-33F2-41B1-B0C1-20C3DCCA7AF1Q53172498-F5A83ADD-307A-46AF-B621-6042FA7FFC17Q58797645-E15B9679-6F9A-4C7C-9F98-188C50993149Q84278082-9EC8B9AA-5085-41EA-9969-1B8B80A0AFCBQ86416870-06BC6911-FCB5-4F30-985E-64D46A4ACF23Q87241202-A732657C-FD33-40DA-8B26-32585A94B8AAQ87421014-925A2ECB-0F96-40F5-BD80-668C59C48D11
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Tristan R A Lane
@ast
Tristan R A Lane
@en
Tristan R A Lane
@es
Tristan R A Lane
@nl
type
label
Tristan R A Lane
@ast
Tristan R A Lane
@en
Tristan R A Lane
@es
Tristan R A Lane
@nl
prefLabel
Tristan R A Lane
@ast
Tristan R A Lane
@en
Tristan R A Lane
@es
Tristan R A Lane
@nl
P106
P31
P496
0000-0002-8681-7075